Learn More
Atezolizumab Mouse, Clone: 6B12, GenScript™
Description
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as immune checkpoint inhibition.
Specifications
Specifications
| Antigen | Atezolizumab |
| Applications | ELISA |
| Classification | Monoclonal |
| Clone | 6B12 |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% sodium azide; pH 7.4 |
| Gene Alias | Tecentriq |
| Host Species | Mouse |
| Immunogen | Atezolizumab |
| Purification Method | Protein A |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.